WHO ICTRP trial
A randomized phase 3 study of two doses of ALIMTA in patients with locally…
EUCTR2004-000815-25-AT · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2004-000815-25-AT |
|---|---|
| Public title | A randomized phase 3 study of two doses of ALIMTA in patients with locally advanced or metastatic Non-Small Cell Lung Cancer who have failed a prior platinum-containing chemotherapy. - JMGX |
| Scientific title | A randomized phase 3 study of two doses of ALIMTA in patients with locally advanced or metastatic Non-Small Cell Lung Cancer who have failed a prior platinum-containing chemotherapy. - JMGX |
| Primary sponsor | Eli Lilly and Company Limited |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Spain;Austria |
| Conditions | Patients with locally advanced or metastatic Non-Smal Cell Lung Cancer who have failed a prior Platinum-containing chemotherapy. MedDRA version: 7.0 Level: LLT Classification code 10059515 |
| Interventions | Trade Name: Alimta Product Name: ALIMTA Product Code: LY231514 disodium Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: pemetrexed CAS Number: 150399-23-8 Current Sponsor code: LY231514 disodium Concentration… |
| Registration date | Feb 15, 2005 |
| Target size | 1000 |
| Secondary IDs | H3E-MC-JMGX;N/A |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: